|
Multiple risk factor control (HbA1c < 7% and BP < 130/80 mmHg or LDLc< 100 mg/dl)
|
Blood test + BP measurement using digital BP monitor
|
Baseline: Prior to intervention deliveryFollow-up: Annual visits post intervention delivery
|
Trial eCRF (Form C, E, F)
|
|
Single risk factor control
|
|
HbA1c (1% point reduction)
|
Fasting blood test
|
Baseline: Prior to intervention deliveryFollow-up: Annual visits post intervention delivery
|
Trial eCRF (Form C, E, F)
|
|
SBP (5 mmHg reduction)
|
BP measurement using digital BP monitor (Omron-T9P)
|
Baseline: Prior to intervention deliveryFollow-up: Annual visits post intervention delivery
|
Trial eCRF (Form C, E, F)
|
|
DBP (5 mmHg reduction)
|
BP measurement using digital BP monitor (Omron-T9P)
|
Baseline: Prior to intervention deliveryFollow-up: Annual visits post intervention delivery
|
Trial eCRF (Form C, E, F)
|
|
LDLc (10 mg/dl reduction)
|
Fasting blood test
|
Baseline: Prior to intervention deliveryFollow-up: Annual visits post intervention delivery
|
Trial eCRF (Form C, E, F)
|
|
Major adverse cardiovascular events
|
Self-reported by patient and physician verified
|
Follow-up: All study related and non-study related clinic visits
|
Trial eCRF (form X)
|
|
Diabetes related micro-vascular complications
|
Self-reported by patient and physician verified
|
Follow-up: All study related and non-study related clinic visits
|
Trial eCRF (form X)
|
|
Quality adjusted life years
|
EQ5D-3 L
|
Baseline: Prior to intervention deliveryFollow-up: Annual visits post intervention delivery
|
Trial eCRF (Form C, E, F)
|
